Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.

NCT Number	NCT07484217
Lead Sponsor	Axsome Therapeutics, Inc.
Conditions	Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Enrollment	508 participants
Start Date	2026-02-23
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-24